SNDX - Syndax Pharmaceuticals, Inc.
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2026 financial results and provide a business update on Monday, November 2, 2026.
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) is expected to be announcing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Syndax Pharmaceuticals to post earnings of ($0.4848) per share and revenue of $81.91 million for the quarter. Individuals may visit the company's upcoming Q3 2026 earnings results page for
BioCryst Pharmaceuticals (NASDAQ: BCRX - Get Free Report) and Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk. Institutional and Insider Ownership 85.9% of BioCryst Pharmaceuticals
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
LOS ANGELES--(BUSINESS WIRE)---- $SNDX--SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law.
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj® (revumenib), the Company's first-in-class menin inhibitor, has been selected by TIME as one of the “Best Inventions of 2026” in the Medical and Healthcare category. TIME's annual list of the Best Inventions features 300 extraordinary inventions changing lives.
SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the
SNDX shareholders saw the market open to losses of more than 11% after the Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of investors who lost money.
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial.
U.S. stock futures were mixed this morning, with the Dow futures gaining around 200 points on Tuesday. Shares of Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) fell sharply in pre-market trading after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.
– Trial did not meet the primary endpoint of annualized rate of FVC decline – – Axatilimab was well tolerated with a safety profile comparable to placebo; no new safety signals were observed – – Axatilimab continues to advance in multiple trials in cGVHD with results expected later this year and early 2028 – NEW YORK, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis (IPF) did not meet its primary endpoint of the annualized rate of decline in forced vital capacity (FVC). The safety and tolerability profile observed in MAXPIRe was consistent with previous clinical studies of axatilimab, with no new safety signals identified.
Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability. Volatility and Risk Syndax Pharmaceuticals has a
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2026, the Company granted inducement awards to purchase up to 213,300 shares of common stock to nine new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Syndax Pharmaceuticals remains a "Strong Buy," driven by label expansion and robust revenue growth for Revuforj and Niktimvo. Company achieved FDA approval for Revuforj in r/r mNPM1 AML and is pursuing pivotal studies to expand into 1st-line AML populations. Niktimvo, already approved for cGVHD, is being advanced into IPF and 1st-line cGVHD, with key phase 2 data readouts expected in Q4 2026.
Syndax Pharmaceuticals, Inc. is positioned for significant growth, driven by Revuforj and Niktimvo, with management reiterating $2B+ U.S. peak sales for Revuforj. Recent SAVE trial data for Revuforj in AML shows 88% ORR and strong MRD negativity, derisking ongoing phase 3 trials and supporting expanding real-world use. SNDX's pipeline features next-gen menin and EGFR inhibitors, targeting high unmet needs in myelofibrosis and NSCLC, with rapid proof-of-concept timelines.
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2026, the Company granted inducement awards to purchase up to 175,000 shares of common stock to nineteen new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A.